ProPhase Labs Inc (NASDAQ:PRPH) saw a significant drop in short interest in June. As of June 30th, there was short interest totalling 800 shares, a drop of 75.8% from the May 30th total of 3,300 shares. Currently, 0.0% of the company’s stock are short sold. Based on an average trading volume of 10,300 shares, the short-interest ratio is presently 0.1 days.

A hedge fund recently bought a new stake in ProPhase Labs stock. Dimensional Fund Advisors LP bought a new stake in ProPhase Labs Inc (NASDAQ:PRPH) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 10,817 shares of the company’s stock, valued at approximately $34,000. Dimensional Fund Advisors LP owned approximately 0.09% of ProPhase Labs as of its most recent SEC filing. 4.31% of the stock is currently owned by institutional investors.

Separately, TheStreet upgraded shares of South Jersey Industries from a “c+” rating to a “b-” rating in a research note on Tuesday.

PRPH traded down $0.05 during trading on Friday, hitting $2.02. The stock had a trading volume of 5,535 shares, compared to its average volume of 15,897. ProPhase Labs has a twelve month low of $2.01 and a twelve month high of $4.00. The business’s 50 day simple moving average is $2.68.

ProPhase Labs (NASDAQ:PRPH) last announced its earnings results on Tuesday, May 14th. The company reported ($0.09) earnings per share for the quarter. The firm had revenue of $2.32 million during the quarter. ProPhase Labs had a negative net margin of 23.26% and a negative return on equity of 14.54%.

About ProPhase Labs

ProPhase Labs, Inc engages in the research, development, manufacture, distribution, marketing, and sale of over-the-counter(OTC) consumer healthcare products, dietary supplements, and other remedies in the United States. The company offers TK Supplements product line include Legendz XL for sexual health; Triple Edge XL, an energy booster and testosterone support; and Super ProstaFlow+ for prostate and urinary health.

Recommended Story: Conference Calls and Individual Investors

Receive News & Ratings for ProPhase Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProPhase Labs and related companies with's FREE daily email newsletter.